Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Common Equity (2020 - 2025)

Agilon Health (AGL) has disclosed Common Equity for 6 consecutive years, with $126.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 73.09% year-over-year to $126.7 million, compared with a TTM value of $126.7 million through Dec 2025, down 73.09%, and an annual FY2025 reading of $126.7 million, down 73.09% over the prior year.
  • Common Equity was $126.7 million for Q4 2025 at Agilon Health, down from $306.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.2 billion in Q2 2021 and bottomed at -$298.2 million in Q1 2021.
  • Average Common Equity over 5 years is $732.9 million, with a median of $780.0 million recorded in 2023.
  • The sharpest move saw Common Equity surged 563.3% in 2021, then tumbled 73.09% in 2025.
  • Year by year, Common Equity stood at $1.1 billion in 2021, then decreased by 4.67% to $1.0 billion in 2022, then crashed by 36.48% to $661.0 million in 2023, then fell by 28.75% to $471.0 million in 2024, then crashed by 73.09% to $126.7 million in 2025.
  • Business Quant data shows Common Equity for AGL at $126.7 million in Q4 2025, $306.1 million in Q3 2025, and $408.9 million in Q2 2025.